GlycoMimetics, Inc. - GLYC STOCK NEWS

GlycoMimetics, Inc. (NASDAQ: GLYC) will host a conference call and webcast to discuss its fourth quarter and year-end financial results for 2021 on March 3, 2022, at 8:30 a.m. ET. Domestic participants can dial in at (844) 413-7154, while international participants can call (216) 562-0466, using participant code 4048456. A webcast replay will be available on the company’s website for 30 days. GlycoMimetics is focused on developing glycobiology-based therapies for cancers and inflammatory diseases, leveraging its unique chemistry platform to create transformative therapies.

GlycoMimetics, Inc. (NASDAQ:GLYC) announced the approval of a non-qualified stock option award for 235,000 shares to Bruce Johnson, the new Senior VP and Chief Commercial Officer. This grant, which serves as an inducement for his employment, includes options for 200,000 shares with a vesting schedule starting February 16, 2023, and 35,000 shares that will vest contingent upon FDA approval of uproleselan and its first commercial sale. The exercise price is set at $1.07, aligning with the closing stock price on the grant date.

GlycoMimetics, Inc. (GLYC) has appointed Bruce Johnson as the new Senior Vice President and Chief Commercial Officer. Johnson brings extensive experience in oncology, having led the commercialization of drugs such as Midostaurin and Venetoclax. His immediate focus will be on developing a commercialization strategy for GlycoMimetics’ lead asset, uproleselan, which is currently in a Phase 3 trial for acute myeloid leukemia (AML) and has received Breakthrough Therapy designation. This strategic hire aims to enhance competitive readiness and scientific education around uproleselan.

GlycoMimetics, Inc. (NASDAQ: GLYC) presented data at the 63rd American Society of Hematology Annual Meeting supporting their dual antagonist GMI-1359 as a novel treatment for acute myeloid leukemia (AML). Preclinical studies at the University of Texas MD Anderson Cancer Center showed that GMI-1359 disrupts tumor-stromal interactions, enhancing the efficacy of existing therapies like venetoclax and FLT3 inhibitors. The data revealed significant improvements in survival rates in mouse models treated with GMI-1359, potentially addressing chemoresistance and preserving healthy bone marrow cells.

GlycoMimetics, Inc. (GLYC) announced the completion of enrollment for 267 patients in its Phase 2 trial for uproleselan, targeting acute myeloid leukemia (AML) in patients aged 60 and above. This milestone paves the way for an interim analysis of event-free survival, crucial for potential advancement to Phase 3 trials and regulatory submissions. Uproleselan, a first-in-class E-selectin antagonist, aims to enhance outcomes in intensive chemotherapy settings. The NCI and the Alliance for Clinical Trials in Oncology collaborated on this study, aiming for a dataset of 650 patients.

GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a non-qualified stock option award on November 22, 2021, for 100,000 shares to Dr. Lisa DeLuca, the new Vice President of Regulatory Affairs. This award is intended to induce her acceptance of employment and is outside the company's 2013 Equity Incentive Plan. The options have an exercise price of $1.84 per share, based on the closing price on the grant date, and will vest over four years. GlycoMimetics focuses on developing glycomimetic drugs, with its flagship candidate, uproleselan, currently in clinical trials for AML.

GlycoMimetics (NASDAQ: GLYC) has announced that Apollomics has successfully dosed the first patient in a Phase 3 clinical trial of APL-106 (uproleselan) for treating adults with relapsed or refractory acute myeloid leukemia (AML) in China. This trial is part of a bridging study aimed at assessing the efficacy of uproleselan in combination with chemotherapy versus chemotherapy alone. The primary endpoint is overall survival, while secondary measures include remission rates and chemotherapy-related side effects. The trial will recruit approximately 140 patients across 20 research centers in China.

GlycoMimetics, Inc. (Nasdaq: GLYC) announced the appointment of Lisa DeLuca, Ph.D., as Vice President of Regulatory Affairs. Dr. DeLuca, an experienced regulatory expert, has held significant roles at various firms, including leading global NDA submissions. Her expertise will enhance GlycoMimetics' engagement with the FDA regarding ongoing trials of uproleselan for acute myeloid leukemia (AML). Uproleselan is currently in Phase 3 trials and has received Breakthrough Therapy Designation from the FDA, aimed at improving treatment outcomes in AML patients.

GlycoMimetics, Inc. (NASDAQ: GLYC) announced the completion of patient enrollment in its pivotal Phase 3 trial evaluating uproleselan in combination with standard chemotherapy for relapsed/refractory acute myeloid leukemia (AML). A total of 388 patients were enrolled across 70 sites in nine countries, aiming for a primary endpoint of overall survival. Topline results are expected after 2022. Uproleselan, designed to target E-selectin, has received Breakthrough Therapy Designation from the U.S. FDA for adult AML patients, potentially marking a shift in treatment paradigms.